Advertisement
On Tuesday, November 6 at 2:40 p.m. Eastern Time, Immtech is scheduled topresent in the Hubbard Room, 5th floor, at the New York Palace Hotel in NewYork City.
Advertisement
Immtech will hold a conference call on Friday, November 9, at 3.00 p.m.(ET) to present an update on the Company's progress. The User Access Code is# 23641366. Investors and interested parties in the U.S. are invited to jointhe call by dialing (888) 338-8374 and callers outside the U.S. should call(706) 902-3163. To register, please call no later than 10 minutes prior tothe scheduled start of the call. Information to access a recording of theconference call will be available starting on November 12 from the ImmtechPharmaceuticals website (http://www.immtechpharma.com).
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializingdrugs to treat infectious diseases, and the company is expanding its targetedmarkets by applying its proprietary pharmaceutical platform to treat otherdisorders. Immtech has advanced clinical programs that include new oraltreatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HATor African sleeping sickness), and a well-defined, expanding library ofcompounds targeting drug-resistant Gram-positive bacteria, fungal infections,Hepatitis C and other serious diseases. Immtech holds the exclusive worldwidelicenses to certain patents, patent applications and technology for productsderived from a proprietary pharmaceutical platform. For additionalinformation, please go to http://www.immtechpharma.com
"Safe Harbor" Statement under the Private Securities Reform Act of 1995:Statements in this press release regarding Immtech Pharmaceuticals, Inc.'sbusiness, including the future prospects for PCP, which are not historicalfacts are "forward- looking statements" that involve risks and uncertainties.Actual results could differ materially from these forward-looking statements.Factors that could cause or contribute to such differences include, but arenot limited to, those discussed under the headings "Management's Discussionand Analysis of Financial Condition and Results of Operations" and "RiskFactors" in Immtech's annual report on Form 10-K for the year ended March 31,2007 and in its other SEC filings and include: (i) Immtech's ability todevelop commercially viable products; (ii) Immtech's ability to achieveprofitability; (iii) Immtech's ability to retain key personnel; (iv) theability of Immtech's scientists and collaborators to discover new compounds;(v) the availability of additional research grants; (vi) Immtech's ability toobtain regulatory approval of its drug candidate, including PCP; (vii) thesuccess of Immtech's clinical trials; (viii) dependence upon and contractualrelationship with partners; (ix) Immtech's ability to manufacture or to have athird party manufacture its drug candidate at a reasonable cost; (x) Immtech'sability to protect its intellectual property; (xi) competition and alternativetechnologies; (xii) Immtech's ability to obtain reimbursement from third partypayers for any product it commercializes; and (xiii) potential exposure tosignificant product liability.
SOURCE Immtech Pharmaceuticals, Inc.
